Latest News

Tiziana Life Sciences initiates trial using nasally administered monoclonal antibody to treat a pers


Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company’s fully-human anti-CD3 monoclonal antibody.

The drug will be provided under the Food & Drug Administration’s individual patient expanded access protocol overseen by researchers at the Brigham and Women’s Hospital (BWH), Harvard.

This is the first time a nasally administered antibody has been given to a patient with SPMS.

Sufferers of multiple sclerosis have limited treatment options with Tysabri, sold by Biogen Inc (NASDAQ:BIIB), one of the few drugs offering relief.

The treatment has been safely administered in a previous trial in people with Covid and was shown to be well-tolerated with no drug-related safety issues.

Nasal Foralumab was developed by Howard Weiner, chairman of Tiziana’s scientific advisory board and a professor at BWH.

He said: “Nasally administered anti-CD3 is an exciting, novel approach that has the ability to provide safe treatment for a form of MS that currently has no effective treatment.

“We are excited to examine this first-in-class approach to treat patients with SPMS for whom no effective treatment option is currently available.”

Infinity Lithium buoyed as European Commission VP reaffirms critical importance of lithium in Europe

Previous article

Argo Blockchain mines the crypto vein amid market boom

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News